Clinical trial
5HT3 Antagonism and Auditory Gating in Schizophrenia
NCT00018850 · US Department of Veterans Affairs, U.S. Fed · Completed
Key facts
| NCT number | NCT00018850 |
|---|---|
| Title | 5HT3 Antagonism and Auditory Gating in Schizophrenia |
| Official title | 5HT3 Antagonism and Auditory Gating in Schizophrenia |
| Lead sponsor | US Department of Veterans Affairs, U.S. Fed |
| Status | Completed |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Behavioral, Drug |
| Interventions | ondansetron, neuropsychological testing, nicotine, haloperidol |
| Start date | Jun 1, 1998 |
| Completion | Jun 1, 2003 |
| First posted | Jul 5, 2001 |
| Last update posted | Jan 21, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: